Rexahn Pharmaceuticals, Inc. Initiates Clinical Trial of Serdaxin to Treat Depression
Rexahn's Phase IIa clinical trial for Serdaxin is designed as a randomized, double blind, dose ranging and placebo-controlled study and will be conducted at multiple sites in the U.S. Serdaxin will be administered as an oral, extended release tablet. Patient enrollment will occur throughout 2009, with preliminary data expected in early 2010.
"We believe that successfully bringing Serdaxin to market will mark a significant development in the treatment of depression and related mood disorders," said Dr. Chang Ahn, CEO of Rexahn Pharmaceuticals. "Also, we are excited about Serdaxin’s potential as a potent neuroprotective agent as demonstrated in two validated animal models of neurodegenerative diseases where depression is a major co-morbidity and patients still face serious unmet needs."
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.